ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q2 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $1 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.